Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04611477
Other study ID # NI/190701/SYNBIOTIC365/OO
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 28, 2020
Est. completion date October 29, 2021

Study information

Verified date September 2020
Source Vedic Lifesciences Pvt. Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluate the effect of Synbiotic 365 (Version 5 and 7) on body composition in overweight and obese individuals as measured by change in body mass index (BMI) and the percentage of body fat from Day 0 to Day 84 when compared to placebo by Dual Energy X-ray Absorptiometry scan (DEXA) for body composition (Body Mass Index, Lean Body Mass, Body Fat, Fat Free Mass).


Recruitment information / eligibility

Status Completed
Enrollment 180
Est. completion date October 29, 2021
Est. primary completion date October 29, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Participants meeting ALL of the following criteria will be recruited for the trial: Inclusion: 1. Male and female participants aged =30 and =60 years. 2. Participants with a BMI in the range of =25 to 34.9 kg/m2. 3. Normal levels of SGOT and SGPT i.e. up to 2.5 times of upper limit of reference range. 4. Normal level of Creatinine i.e. up to 1.5 times of upper limit of reference range. 5 Alkaline Phosphatase i.e. up to 1.5 times of upper limit of reference range 6. Participants having At least 3 of the following five metabolic risk factors: i. Waist circumference: Men: = 102 cm (40.15 inches); Women =88 cm (34.65 inches) ii. Triglycerides levels >150 mg/dL iii. Blood pressure =130 mm Hg (systolic, SBP) and/or =85 mm Hg(diastolic, DBP); iv. Fasting blood glucose = 100 mg/ dL v. Low HDL level: Men: < 40 mg/dL; Women: < 50 mg/dL.. 7. Participants willing to complete all the study procedures including study-related questionnaires and comply with the study requirements. 8. Participants willing to abstain from the restricted supplements and medications prior to inclusion and throughout the study period. 9. Participants ready to give voluntary, written, informed consent to participate in the study. 10. Participants willing to continue the same diet and exercise regime throughout the study period. Exclusion: 1. Individuals having a history of smoking or currently smoking and also using any form of tobacco preparations. 2. Participants diagnosed with type II diabetes mellitus or undiagnosed cases of hyperglycemia with fasting blood sugar > 170 mg/dl. 3. Participants with blood pressure =150 mm Hg (systolic, SBP) and/or = 99 mm Hg (diastolic, DBP) 4. Inability to walk independently 5. History of significant weight instability (defined as > 2 kg of weight loss over last 3 months) 6. Participants currently on diuretics, metformin or thyroid supplements. Presence of unstable, acutely symptomatic, or life-limiting illness. 7. Any significant neurological and psychiatric condition which may affect the participation and inference of the study's end points. 8 Unwillingness or inability to be randomized to any one of the three intervention groups. 9 Continuous participation in randomly assigned lifestyle intervention program for six months. 10 Bilateral hip replacements. 11 Unable to give consent. 12 Known cases of hypothyroidism. 13 Abnormal TSH value, out of reference range (<0.4µIU/mL and > 4.0µIU/mL). 14 Females with the history of irregular menses or any other gynecological disorder such as (polycystic ovarian syndrome (PCOS), hormonal disturbances, etc). 15 History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic disorders, that in the judgment of the investigator, would interfere with the participant's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the participant at undue risk.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Rice Hulk
Placebo
Synbiotic365 Ver 5
Active Comparator
Synbiotic365 Ver 7
Active Comparator

Locations

Country Name City State
India Shri Madhumadhav Clinic Mumbai Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Vedic Lifesciences Pvt. Ltd.

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in body mass index (BMI) and the percentage of body fat f To investigate the effect of Synbiotic 365 (Version 5 and 7) on body composition in overweight and obese individuals as measured by change in body mass index (BMI) and the percentage of body fat from Day 0 to Day 84 when compared to placebo by Dual Energy X-ray Absorptiometry scan (DEXA) for body composition Day 0 (Baseline) to Day 84
Secondary • Total body weight change in comparison to placebo on day 28, 56 and 84, from baseline, as assessed by weighing scale method. Day 0 (Baseline) to Day 84
Secondary • Change in central obesity in comparison to placebo on day 28, 56 and 84, from baseline as assessed by the anthropometric index of waist-to-hip ratio. Day 0 (Baseline) to Day 84
Secondary • Change in coronary risk in comparison to placebo on day 84 from baseline. Day 0 (Baseline) to Day 84
Secondary • Change in blood glucose metabolism in comparison to placebo on day 84 from baseline as assessed by HOMA-IR [(fasting Glucose x fasting Insulin) /405)]. Day 0 (Baseline) to Day 84
Secondary • Change in systemic inflammation in comparison to placebo on day 84 from baseline as assessed by hs-CRP test. Day 0 (Baseline) to Day 84
Secondary • Change in health-related quality of life (HRQL) scores in comparison to placebo on day 28, 56 and 84 from baseline, as assessed by Gastrointestinal Quality of Life Index (GIQLI). Day 0 (Baseline) to Day 84
Secondary • Change in satiety in comparison to placebo on day 28, 56 and 84, from baseline as assessed by the Three-Factor Eating Questionnaire (TFEQ) for satiety. Day 0 (Baseline) to Day 84
Secondary • The change in vital signs monitoring on all the study visits from baseline. Day 0 (Baseline) to Day 84
Secondary • The change in liver and renal safety parameters. Day 0 (Baseline) to Day 84
Secondary • Adverse and serious adverse events recorded during the study duration on IP consumption, as compared to placebo. Day 0 (Baseline) to Day 84
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03994419 - PErioperAtive CHildhood ObesitY
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03602001 - Attentive Eating for Weight Loss N/A
Recruiting NCT06269159 - The Power of 24-hour: Co-designing Intervention Components
Completed NCT03377244 - Healthy Body Healthy Souls in the Marshallese Population N/A
Completed NCT02996864 - Location-based Smartphone Technology to Guide College Students Healthy Choices Ph II N/A
Terminated NCT03914066 - A Group-based Treatment of Overweight and Obesity in Primary Care N/A
Completed NCT04647149 - Effects of Early and Delayed Time-restricted Eating in Adults With Overweight and Obesity N/A
Completed NCT03685656 - Effect of ANACA3 Slimming Gel on Loss of Abdominal and Thigh Circumferences in Healthy Volunteers N/A
Completed NCT05051579 - A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities Phase 2
Active, not recruiting NCT05330247 - Cut Down on Carbohydrate in the Dietary Therapy of Type 2 Diabetes - The Meal Box Study N/A
Completed NCT03599115 - Effects of Inhibitory Control Training in Eating Behaviors N/A
Recruiting NCT06094231 - Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study N/A
Recruiting NCT05938894 - Train Your Brain - Executive Function N/A
Recruiting NCT05987306 - A Self-compassion Focused Intervention for Internalized Weight Bias and Weight Loss N/A
Completed NCT03792685 - Looking for Personalized Nutrition for Obesity/Type 2 Diabetes Mellitus Prevention N/A
Completed NCT05055362 - Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study N/A
Completed NCT04520256 - Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy Phase 2/Phase 3
Completed NCT04979234 - A Single Centre, Prospective Feasibility Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) on Severe Obstructive Sleep Apnea Syndrome N/A
Not yet recruiting NCT06338709 - Clinical Study Protocol for the Assessment of Safety and Efficacy of the BARICLIP® N/A